First-in-human data from Phase 1 trial of MZE782 support best- and first-in-class potential; two Phase 2 proof-of-concept trials in phenylketonuria (PKU) and chronic kidney disease (CKD) expected to initiate in 2026
Read more at globenewswire.comMaze Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights
Provided By GlobeNewswire – Last update: